**Pcat29 Lncrna**

MechRNA: prediction of IncRNA mechanisms from RNA–RNA and ... The IncRNA PCAT29 Inhibits Oncogenic Phenotypes in ... The IncRNA PCAT29 Inhibits Oncogenic Phenotypes in ... DTIC ADA612750: Biological and Clinical Characterization ... (PDF) The IncRNA PCAT29 inhibits oncogenic phenotypes in ... The IncRNA DRAIC/PCAT29 Locus Constitutes a Tumor ... Prediction of IncRNA–disease associations based on ... A Long Noncoding RNA Suppresses Prostate Tumorigenesis ... Identification of lncRNA Signature Associated With Pan ... The IncRNA DRAIC/PCAT29 Locus Constitutes a Tumor ... The IncRNA PCAT29 inhibits oncogenic phenotypes in ... PCAT29 - LncRNAWiki - Lncrna.big.ac.cn PROSTATE CANCER-ASSOCIATED TRANSCRIPT 29, NONCODING; PCAT29 The IncRNA DRAIC/PCAT29 locus constitutes a tumor ... LncRNA PCAT29 suppresses cell proliferation, invasion, and ... Pcat29 Lncrna A Long Noncoding RNA Suppresses Prostate Tumorigenesis ... Long non-coding RNA PCAT29 regulates the growth, migration ... The IncRNA DRAIC/PCAT29 Locus Constitutes a Tumor ... PCAT29 Gene - GeneCards | PCAT29 RNA Gene

MechRNA: prediction of IncRNA mechanisms from RNA–RNA and ... Collectively, PCAT29 is a tumor-suppressive IncRNA of prognostic and therapeutic relevance in prostate cancer. In addition, we have performed transcriptome analysis to identify a set of AR regulated IncRNAs. AR plays a critical role in the development and progression of prostate cancer.

The IncRNA PCAT29 Inhibits Oncogenic Phenotypes in ...
A lncRNA, PCAT29 is regulated by AR, FOXA1, and NKX3-1 Malik and colleagues recently reported a tumor-suppressive IncRNA, PCAT29, whose expression is repressed by AR (13). Interestingly, PCAT29 gene is located 20 kb downstream of DRAIC.

The IncRNA PCAT29 Inhibits Oncogenic Phenotypes in ...
Here the novel lncRNA, Prostate Cancer-Associated Transcript 29 (PCAT29), is characterized along with its relationship to the androgen receptor (AR). PCAT29 is suppressed by dihydrotestosterone (DHT) and upregulated upon castration therapy in a prostate cancer xenograft model.

DTIC ADA612750: Biological and Clinical Characterization ...
LncRNA colon cancer associated transcript-1 (CCAT1), located on chromosome 8q24.21, was first identified as an oncogene in colorectal cancer by Nissan and colleagues. The overexpression of CCAT1 was recently proven to activate the initiation and progression in a variety of cancers (13-16) by sponging miRNAs such as MIR-490-3P, MIR-218-5P, and MIR-7.

(PDF) The IncRNA PCAT29 inhibits oncogenic phenotypes in ...
PCAT29 Approved Name. prostate cancer associated transcript 29 (non-protein coding) Disease. prostate cancer Chromosome. 15q23 RefSeq ID. NR_126437 OMIM ID. 616273 Ensembl ID. ENSG00000259641 pubmed IDs. 25030374 Sequence

The IncRNA DRAIC/PCAT29 Locus Constitutes a Tumor ...

Prediction of IncRNA–disease associations based on ...
The IncRNA PCAT29 inhibits prostate cancer cell growth and migration and is suppressed by AR.

A Long Noncoding RNA Suppresses Prostate Tumorigenesis ...
Full-length PCAT29 is 694 bp long. PCAT29 shows no protein-coding potential. RNA sequencing data revealed highest expression of PCAT29 in breast, lymphoid tissue, and prostate, with little to no expression in other tissues examined. PCAT29 was detected in the nucleus of LNCaP and PC3 prostate cancer cells.

Identification of lncRNA Signature Associated With Pan ...
LncRNA PCAT29 suppresses cell proliferation, invasion, and migration in renal carcinoma by regulating FLOT1. Background. LncRNA PCAT29 has been reported to play a role in the development of cancer; the role of FLOT1 in renal carcinoma has been also identified.

**Creative Commons 4.0 (PCAT29)** is a type of IncRNA and has been featured as an androgen-regulated tumor suppressor in prostate cancer [14].

**Here, we report a novel tumor-suppressive locus on human chromosome 15q23 that contains two multiexonic IncRNA genes of 100 kb each: DRAIC (LOC145837) and the recently reported PCAT29.** The DRAIC IncRNA was identified from RNA-seq data and is downregulated as prostate cancer cells progress from an androgen-dependent (AD) to a castration-resistant (CR) state.

**Major finding:** The IncRNA PCAT29 inhibits prostate cancer cell growth and migration and is suppressed by AR. Clinical relevance: Low PCAT29 expression may identify patients at higher risk for prostate cancer recurrence. Impact: PCAT29 is a tumor-suppressive IncRNA of prognostic and therapeutic relevance in prostate cancer.

**We applied MechRNA on a number of recently identified cancer-related IncRNAs (PCAT1, PCAT29 and AR-Lnc1) and also on two well-studied IncRNAs (PCA3 and 7SL). This led to the identification of hundreds of high confidence potential targets for each IncRNA and corresponding mechanisms.**

**624 LncRNA PCAT29 regulates breast cancer growth** JBUON 2020; 25(2): 624 compared to the NC transfected cells. We also found that PCAT29 overexpression resulted in inhibition of colony formation by the MDA-MB-231 cells. The PCAT29 inhibits induces apoptosis in triple negative breast cancer cells. The underlying mechanism for the decrease in

**Here, the novel IncRNA, prostate cancer-associated transcript 29 (PCAT29), is characterized along with its relationship to the androgen receptor. PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model.**

**PCAT29 (Prostate Cancer Associated Transcript 29) is an RNA Gene, and is affiliated with the IncRNA class. Diseases associated with PCAT29 include Skin Melanoma and Brain Glioma.**

**The framework identified a 5-IncRNA signature (ENSG00000206567, PCAT29, ENSG00000257989, LOC388282, and LINC00339) from TCGA training studies (n=1,878). The identified IncRNAs are significantly associated (all P<1.48E-11) with overall survival (OS) of the TCGA cohort (n=4,231).**

**A second tumor-suppressive IncRNA PCAT29, located 20 kb downstream of DRAIC, is regulated identically by AR and FOXA1 and also suppresses cellular migration and metastasis.**

Copyright code : 34c4d1bc97b98af3ef4d51fa3f8e28ae.